Tracey McCain
Fortune : 742 391 $ au 31/05/2026
Fortune : 742 391 $ au 31/05/2026
Tracey L.
McCain is currently an Independent Director at Kiniksa Pharmaceuticals Ltd. since 2018, an Independent Director at Kiniksa Pharmaceuticals International Plc since 2024, and a Trustee at Dana-Farber Cancer Institute, Inc. Former roles include Independent Director at ImmunoGen, Inc. from 2021 to 2024, Secretary, Chief Legal & Compliance Officer at Blueprint Medicines Corp.
from 2016 to 2025, Senior Vice President & Head-Legal at Genzyme Therapeutics Ltd. in 2016, General Counsel at Genzyme Corp.
from 1997 to 2016, and Associate at Palmer & Dodge LLP.
Education includes an undergraduate degree from the University of Pennsylvania in 1989 and a graduate degree from Columbia Law School in 1992.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,03% | 29/05/2026 | 15 345 ( 0,03% ) | 742 391 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Directeur/Membre du Conseil | 01/02/2018 |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Compliance Officer | 01/10/2025 |
| IMMUNOGEN, INC. | Directeur/Membre du Conseil | 12/02/2024 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Conseiller Juridique Général | 02/09/2016 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Conseiller Juridique Général | 01/09/2016 |
Palmer & Dodge LLP
Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 9 |
|---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Palmer & Dodge LLP
Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Columbia Law School
Columbia Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and delivers therapeutic medicines for patients suffering from cardiovascular diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national